HRP20100230T1 - NOVI 2-SUPSTITUIRANI D-HOMO-ESTRA-1,3,5(10)-TRIENI KAO INHIBITORI 17ß-HIDROKSISTEROIDNE DEHIDROGENAZE TIPA 1 - Google Patents
NOVI 2-SUPSTITUIRANI D-HOMO-ESTRA-1,3,5(10)-TRIENI KAO INHIBITORI 17ß-HIDROKSISTEROIDNE DEHIDROGENAZE TIPA 1 Download PDFInfo
- Publication number
- HRP20100230T1 HRP20100230T1 HR20100230T HRP20100230T HRP20100230T1 HR P20100230 T1 HRP20100230 T1 HR P20100230T1 HR 20100230 T HR20100230 T HR 20100230T HR P20100230 T HRP20100230 T HR P20100230T HR P20100230 T1 HRP20100230 T1 HR P20100230T1
- Authority
- HR
- Croatia
- Prior art keywords
- homo
- estra
- oxo
- trien
- substituted
- Prior art date
Links
- 101710088194 Dehydrogenase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 8
- 238000004519 manufacturing process Methods 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 230000001419 dependent effect Effects 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 239000000262 estrogen Substances 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- 230000002280 anti-androgenic effect Effects 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 239000003418 antiprogestin Substances 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical group CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 102000004026 17-Hydroxysteroid Dehydrogenases Human genes 0.000 claims 1
- 108010082514 17-Hydroxysteroid Dehydrogenases Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 claims 1
- -1 alkylaryl radical Chemical class 0.000 claims 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000002149 gonad Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 abstract 1
- 101710147298 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 abstract 1
- 101710174215 Estradiol 17-beta-dehydrogenase 1 Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
2-Supstituirani D-homo-estratrieni opće formule I, gdje je R2 je zasićena ili nezasićena C1-C8-alkilna skupina, aralkil ili alkilaril radikal, C1-C8-alkiloksi skupina ili atom halogena, R13 je atom vodika ili metilna skupina, R17 je vodik ili atom fluora, gdje isprekidane linije u B prstenu i D prstenu steroidne molekule mogu biti dodatne dvostruke veze, i njihove farmaceutski prihvatljive soli s izuzetkom spoja 2-metoksi-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ola. Patent sadrži još 13 patentnih zahtjeva.
Claims (14)
1. 2-Supstituirani D-homo-estratrieni opće formule I,
[image]
gdje je
R2 je zasićena ili nezasićena C1-C8-alkilna skupina, aralkil ili alkilaril radikal, C1-C8-alkiloksi skupina ili atom halogena,
R13 je atom vodika ili metilna skupina,
R17 je vodik ili atom fluora,
gdje isprekidane linije u B prstenu i D prstenu steroidne molekule mogu biti dodatne dvostruke veze, i njihove farmaceutski prihvatljive soli s izuzetkom spoja 2-metoksi-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ola.
2. 2-Supstituirani D-homo-estra-1,3,5(10)-trieni prema zahtjevu 1, naznačeni time da R2 je C1-C5-alkoksi, C1-C5-alkil ili C2-C3-alkenil radikal ili je brom ili klor.
3. 2-Supstituirani D-homo-estra-1,3,5(10)-trieni prema zahtjevu 1, naznačeni time da R2 je metoksi ili etoksi radikal, metil, etil ili propil radikal, i alil radikal.
4. 2-Supstituirani D-homo-estra-1,3,5(10)-trieni prema zahtjevu 1, naznačeni time da R13 je atom vodika.
5. 2-Supstituirani D-homo-estra-1,3,5(10)-trieni prema zahtjevu 1, naznačeni time da su
2) 2-etoksi-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol
3) 2-kloro-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol 2
4) 2-bromo-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol 3
5) 2-jodo-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol 4
6) 2-kloro-17α-floro-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol 5a
7) 2-kloro-17β-floro-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol 5b
8) 2-bromo-17α-floro-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol
9) 2-bromo-17β-floro-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol
10) 2-(2-feniletil)-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol 6
11) 2-alil-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol 7
12) 2-alil-17α-floro-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol
13) 2-alil-17β-floro-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol
14) 2-kloro-17a-okso-17a-homo-estra-1,3,5(10),16-tetraen-3-ol
15) 2-bromo-17a-okso-17a-homo-estra-1,3,5(10),16-tetraen-3-ol 8
16) 2-alil-17a-okso-17a-homo-estra-1,3,5(10),16-tetraen-3-ol
17) 2-propil-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol
18) 2-metoksi-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
19) 2-etoksi-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
20) 2-kloro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
21) 2-bromo-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
22) 2-jodo-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
23) 2-kloro-17α-floro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
24) 2-kloro-17β-floro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
25) 2-bromo-17α-floro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
26) 2-bromo-17β-floro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
27) 2-alil-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
28) 2-alil-17α-floro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
29) 2-alil-17β-floro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
30) 2-kloro-17a-okso-17a-homo-18a-homo-estra-1,3,5(10),16-tetraen-3-ol
31) 2-bromo-17a-okso-17a-homo-18a-homo-estra-1,3,5(10),16-tetraen-3-ol
32) 2-alil-17a-okso-17a-homo-18a-homo-estra-1,3,5(10),16-tetraen-3-ol
33) 2-propil-17a-okso-17a-homo-18a-homo-estra-1,3,5(10)-trien-3-ol
6. 2-Supstituirani D-homo-estra-1,3,5(10)-trieni prema jednom od zahtjeva 1 do 5 ili 2-metoksi-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol naznačeni time da su za proizvodnju lijeka.
7. Upotreba 2-supstituiranih D-homo-estra-1,3,5(10)-triena prema jednom od zahtjeva 1 to 5 ili 2-metoksi-17a-okso-17a-homo-estra-1,3,5(10)-trien-3-ol naznačena time da je za proizvodnju lijeka za profilaksu i terapiju bolesti ovisnih o estrogenu na koje pozitivno utječe inhibicija 17β-hidroksisteroidnih dehidrogenaza.
8. Upotreba 2-supstituiranih D-homo-estra-1,3,5(10)-triena prema zahtjevu 7, naznačena time da se barem jedan daljnji aktivni spoj koristi u kombinaciji za proizvodnju lijeka.
9. Upotreba 2-supstituiranih D-homo-estra-1,3,5(10)-triena prema zahtjevu 8, naznačena time da je daljnji aktivni spoj antiandrogen, anti-gestagen, inhibitor aromataze ili anti-estrogen.
10. Upotreba 2-supstituiranih D-homo-estra-1,3,5(10)-triena prema jednom od zahtjeva 7 do 9, naznačena time da je za proizvodnju lijeka za profilaksu i terapiju hormonski-ovisnih tumora muških i ženskih gonada, te muških i ženskih spolnih organa, uključujući mliječne žlijezde.
11. Upotreba 2-supstituiranih D-homo-estra-1,3,5(10)-triena prema zahtjevu 10 naznačena time da je za proizvodnju lijeka za profilaksu i terapiju karcinoma dojke.
12. Upotreba 2-supstituiranih D-homo-estra-1,3,5(10)-triena prema zahtjevu 10 naznačena time da je za proizvodnju lijeka za liječenje karcinoma prostate.
13. Upotreba 2-supstituiranih D-homo-estra-1,3,5(10)-triena prema zahtjevu 10 naznačena time da je za proizvodnju lijeka za liječenje endometrioze.
14. Farmaceutski pripravci koji sadrže barem jedan spoj opće formule I prema jednom od zahtjeva 1 do 5 ili 2-metoksi-17a-okso-17a-homoestra-1,3,5(10)-trien-3-ol i po potrebi barem jednog daljnjeg aktivnog spoja zajedno sa farmaceutski prihvatljivim ekscipijentima i/ili nosačima, te je daljnji aktivni spoj antiandrogen, anti-gestagen, inhibitor aromataze ili anti-estrogen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004032673A DE102004032673A1 (de) | 2004-07-02 | 2004-07-02 | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
| PCT/EP2005/007314 WO2006003012A1 (de) | 2004-07-02 | 2005-07-04 | NEUE 2-SUBSTITUIERTE D-HOMO ESTRA-1,3,5(10)-TRIENE ALS INHIBITOREN DER 17ß-HYDROXYSTEROIDDEHYDROGENASE TYP 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100230T1 true HRP20100230T1 (hr) | 2010-06-30 |
Family
ID=35106828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100230T HRP20100230T1 (hr) | 2004-07-02 | 2010-04-20 | NOVI 2-SUPSTITUIRANI D-HOMO-ESTRA-1,3,5(10)-TRIENI KAO INHIBITORI 17ß-HIDROKSISTEROIDNE DEHIDROGENAZE TIPA 1 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1763534B1 (hr) |
| JP (1) | JP4871274B2 (hr) |
| KR (1) | KR20070035059A (hr) |
| CN (1) | CN1980949B (hr) |
| AT (1) | ATE458744T1 (hr) |
| AU (1) | AU2005259329B8 (hr) |
| BR (1) | BRPI0511394A (hr) |
| CA (1) | CA2571760C (hr) |
| CR (1) | CR8854A (hr) |
| DE (2) | DE102004032673A1 (hr) |
| DK (1) | DK1763534T3 (hr) |
| EA (1) | EA011455B1 (hr) |
| EC (1) | ECSP077160A (hr) |
| ES (1) | ES2340401T3 (hr) |
| HK (1) | HK1103745A1 (hr) |
| HR (1) | HRP20100230T1 (hr) |
| IL (1) | IL180171A0 (hr) |
| MX (1) | MX2007000108A (hr) |
| NO (1) | NO20070605L (hr) |
| NZ (1) | NZ552515A (hr) |
| PL (1) | PL1763534T3 (hr) |
| PT (1) | PT1763534E (hr) |
| UA (1) | UA92324C2 (hr) |
| WO (1) | WO2006003012A1 (hr) |
| ZA (1) | ZA200700958B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| DE102007040243A1 (de) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| US9850272B2 (en) | 2013-06-25 | 2017-12-26 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| US9663549B2 (en) | 2013-06-25 | 2017-05-30 | Forendo Pharma Ltd. | Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase |
| CN107207562B (zh) | 2014-12-23 | 2020-03-06 | 佛恩多制药有限公司 | 17β-HSD1抑制剂的前药 |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| UA126342C2 (uk) | 2017-06-08 | 2022-09-21 | Форендо Фарма Лтд | 15-бета-[3-пропанамідо]-заміщені естра-1,3,5(10)-трієн-17-он-сполуки і їх 17-оксими для використання в інгібуванні 17-бета-гідроксистероїддегідрогеназ |
| SG11202105795XA (en) | 2018-12-05 | 2021-06-29 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005835A (en) * | 1960-09-13 | 1961-10-24 | Searle & Co | D-homo-18-norestra-1, 3, 5(10)-trien-17alpha-ones and intermediates thereto |
| GB1346691A (en) * | 1970-06-12 | 1974-02-13 | Inst Khim Prirodnykh Soedineny | Stereospecific method for preparing estrane compounds of natural configuration |
| JPH06279488A (ja) * | 1993-03-29 | 1994-10-04 | Kuraray Co Ltd | 新規なステロイド誘導体および骨粗鬆症治療剤 |
| PL343862A1 (en) * | 1998-03-11 | 2001-09-10 | Endorech | Inhibitors of type 5 and type 3 17β−hydroxysteroid dehydrogenase and methods for their use |
| DE10151365A1 (de) * | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
| WO2003017974A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
| DE10307103A1 (de) * | 2003-02-19 | 2004-09-09 | Schering Ag | Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate |
| DE102004032674A1 (de) * | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
-
2004
- 2004-07-02 DE DE102004032673A patent/DE102004032673A1/de not_active Ceased
-
2005
- 2005-04-07 UA UAA200701040A patent/UA92324C2/ru unknown
- 2005-07-04 BR BRPI0511394-6A patent/BRPI0511394A/pt not_active IP Right Cessation
- 2005-07-04 AT AT05768705T patent/ATE458744T1/de active
- 2005-07-04 JP JP2007518557A patent/JP4871274B2/ja not_active Expired - Fee Related
- 2005-07-04 NZ NZ552515A patent/NZ552515A/en not_active IP Right Cessation
- 2005-07-04 ES ES05768705T patent/ES2340401T3/es active Active
- 2005-07-04 EA EA200700103A patent/EA011455B1/ru not_active IP Right Cessation
- 2005-07-04 WO PCT/EP2005/007314 patent/WO2006003012A1/de active Application Filing
- 2005-07-04 AU AU2005259329A patent/AU2005259329B8/en not_active Expired - Fee Related
- 2005-07-04 CA CA2571760A patent/CA2571760C/en not_active Expired - Fee Related
- 2005-07-04 EP EP05768705A patent/EP1763534B1/de active Active
- 2005-07-04 DE DE502005009091T patent/DE502005009091D1/de active Active
- 2005-07-04 KR KR1020077002617A patent/KR20070035059A/ko not_active Application Discontinuation
- 2005-07-04 DK DK05768705.5T patent/DK1763534T3/da active
- 2005-07-04 PL PL05768705T patent/PL1763534T3/pl unknown
- 2005-07-04 PT PT05768705T patent/PT1763534E/pt unknown
- 2005-07-04 MX MX2007000108A patent/MX2007000108A/es active IP Right Grant
- 2005-07-04 CN CN2005800225714A patent/CN1980949B/zh not_active Expired - Fee Related
-
2006
- 2006-12-19 IL IL180171A patent/IL180171A0/en unknown
-
2007
- 2007-01-10 EC EC2007007160A patent/ECSP077160A/es unknown
- 2007-01-11 CR CR8854A patent/CR8854A/es not_active Application Discontinuation
- 2007-02-01 NO NO20070605A patent/NO20070605L/no not_active Application Discontinuation
- 2007-02-01 ZA ZA200700958A patent/ZA200700958B/en unknown
- 2007-11-08 HK HK07112172.8A patent/HK1103745A1/xx unknown
-
2010
- 2010-04-20 HR HR20100230T patent/HRP20100230T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2340401T3 (es) | 2010-06-02 |
| CA2571760A1 (en) | 2006-01-12 |
| AU2005259329B8 (en) | 2011-11-24 |
| AU2005259329A1 (en) | 2006-01-12 |
| MX2007000108A (es) | 2007-03-09 |
| DK1763534T3 (da) | 2010-05-17 |
| CN1980949B (zh) | 2010-05-05 |
| PT1763534E (pt) | 2010-04-27 |
| EP1763534B1 (de) | 2010-02-24 |
| ZA200700958B (en) | 2008-07-30 |
| CN1980949A (zh) | 2007-06-13 |
| EP1763534A1 (de) | 2007-03-21 |
| WO2006003012A1 (de) | 2006-01-12 |
| KR20070035059A (ko) | 2007-03-29 |
| PL1763534T3 (pl) | 2010-07-30 |
| CR8854A (es) | 2007-08-28 |
| UA92324C2 (en) | 2010-10-25 |
| ATE458744T1 (de) | 2010-03-15 |
| DE102004032673A1 (de) | 2006-01-26 |
| JP2008504337A (ja) | 2008-02-14 |
| JP4871274B2 (ja) | 2012-02-08 |
| IL180171A0 (en) | 2007-06-03 |
| EA200700103A1 (ru) | 2007-08-31 |
| CA2571760C (en) | 2011-11-22 |
| EA011455B1 (ru) | 2009-04-28 |
| NO20070605L (no) | 2007-02-01 |
| NZ552515A (en) | 2010-07-30 |
| HK1103745A1 (en) | 2007-12-28 |
| DE502005009091D1 (de) | 2010-04-08 |
| BRPI0511394A (pt) | 2007-12-04 |
| AU2005259329B2 (en) | 2011-11-10 |
| ECSP077160A (es) | 2007-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100230T1 (hr) | NOVI 2-SUPSTITUIRANI D-HOMO-ESTRA-1,3,5(10)-TRIENI KAO INHIBITORI 17ß-HIDROKSISTEROIDNE DEHIDROGENAZE TIPA 1 | |
| KR102255778B1 (ko) | 질환의 치료를 위한 ｋｄｍ１ａ 저해인자 | |
| RU2015107733A (ru) | Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения | |
| TW200602035A (en) | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | |
| DK1678166T3 (da) | Proteinkinaseinhibitorer | |
| MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
| CN1126473A (zh) | 化学组合物 | |
| WO2006003013B1 (de) | NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1 | |
| US10759803B2 (en) | Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto | |
| BR112016014326B1 (pt) | Compostos antiandrogênios não esteroidais e moduladores seletivos do receptor de androgênio com uma porção piridil, uso dos mesmos, composições farmacêuticas e kit | |
| NO20025510D0 (no) | Tienodibenzoazulenforbindelser som tumor nekrose faktor inhibitorer | |
| JP2022544031A (ja) | リシルオキシダーゼのジフルオロハロアリルアミンスルホン誘導体阻害剤、調製方法、及びそれらの使用 | |
| CN101835747A (zh) | 苯并咪唑衍生物 | |
| WO2007137098A2 (en) | Sulfonyl-substituted bicyclic compounds as modulators of ppar | |
| US7732493B2 (en) | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 | |
| KR102606375B1 (ko) | N-방향족 아미드류 화합물 및 이의 제조 방법과 용도 | |
| EP0009944A3 (en) | Lysosomotropic detergent therapeutic agents and use thereof | |
| ITMI20042475A1 (it) | Uso di derivati tiazolidinonici come agenti terapeutici | |
| WO2016102775A1 (en) | PRODRUGS OF 17β-HSD1 -INHIBITORS | |
| CN103980289A (zh) | 噻吩并噻喃并吡唑类化合物及其医药应用 | |
| JP7136910B2 (ja) | 乾性眼の予防または治療のための組成物 | |
| AU2015256266B2 (en) | BH4 antagonists and methods related thereto | |
| RU2005128830A (ru) | Обладающие противоопухолевым действием 2-замещенные d-гомоэстра-1, 3, 5( 10 )-триен-3-илсульфаматы | |
| WO1998023612A1 (en) | 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists | |
| ATE437639T1 (de) | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)- cyclohexa-2,5-dienone verbindungen und ihre analoge als therapeutische wirkstoffe |